FDA Approves Lantheus Brain-Imaging Agent for Alzheimer's Assessment
LNTH has more than doubled off its 52-week low of $49.67.
Summary
The FDA approved Lantheus' radioactive brain-imaging agent for assessing Alzheimer's disease. The agent is named TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-labeled tau PET imaging agent. This is a new product approval, expanding the company's diagnostic portfolio in a high-demand area. The approval comes amid Lantheus' pending $8B acquisition by Curium, and could strengthen the deal's value or attract competing interest. No financial terms were disclosed, but the approval is a material regulatory milestone.
At the time of this announcement, LNTH was trading at $101.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $49.67 to $111.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.